HBV/G Infection of an Apheresis Donor

Slides:



Advertisements
Similar presentations
A PROSPECTIVE STUDY OF POLYMERASE CHAIN REACTION TESTING ON POOLED PLASMA VS. INDIVIDUAL DONATION HIV P24 TESTING.
Advertisements

HBsAg+ candidate blood donors HBV genotypes Number Origin(s) A1 43 S. Africa A2 72 Poland B 126 Hong Kong Malaysia Taiwan Thailand C 90 Hong Kong Malaysia.
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013.
HCV-HBV co-infection in Russian Federation Chumakov Institute of Poliomyelitis and Viral Encephalitis, Moscow Karen Kyuregyan VIII Annual Conference of.
Nucleic Acid Testing vs Infectivity Michael P. Busch, M.D., Ph.D. Blood Centers of the Pacific Blood Systems, Inc. EPFA, Lisbon Portugal May, 2001.
F. Kourgia, M. Vini, E. Zervou
Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.
COBAS TaqMan 48 Sales Brochure
Testing Source Plasma for Hepatitis B Virus by Nucleic Acid Testing Blood Products Advisory Committee Meeting Blood Products Advisory Committee Meeting.
PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.
Limitations of HBsAg testing in the screening of blood donors Wolfram H. Gerlich Institute of Medical Virology University Giessen, Germany SoGAT XVI Langen.
Lookback study for transfusion- related HBV infection in Japan Tokyo Metropolitan Red Cross Blood Center Masahiro Satake.
Faculty of Allied Medical Sciences Clinical Immunology & Serology Practice (MLIS 201)
BioLife Plasma Services Experience with HBV NAT Testing
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.
SOGAT Validation of HCV-RNA detection in small test pools on cadaveric samples Marco Koppelman #, Theo Cuypers #, Mirjam de Waal #, Maarten.
Michael Chudy, Paul-Ehrlich-Institut SoGAT XVIII, Bethesda MD
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
E A 1 Parvovirus B19 and HAV Screening of Whole Blood Donations SL Stramer, KL Kane, ML Beyers, RY Dodd, American Red Cross and RIF Smith, National.
Level of viraemia and genotype characteristics of Parvo B19 in blood donors and patients Brojer E, Grabarczyk P Depatment of Immuhematology Institute of.
Parvovirus B19 Genotype 2 Plasma, Sourced from the US Dr Sally A. Baylis, Division of Virology NIBSC.
SoGAT June 14, 2006 HCV-RNA and HIV-RNA detection in small test pools of cadaveric samples for viral safety of tissue transplants Maarten Koot#,
1 B19 Testing of Plasma for Fractionation: Current Thinking Mei-ying W Yu, PhD Division of Hematology CBER/FDA SoGAT XVII May 26-27, 2004.
SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.
HBV screening Further improvement of blood safety based on the knowledge deduced from the results on analysis of the donor’s sera positive for HBV DNA.
Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.
Performance of Chiron Quantitative and Qualitative HBV PCR Assay and Confirmation of HBV Yield Cases Yiu-Lian Fong, Ph.D, Associate Director June 13, 2007.
Natural history of HBV infection (adapted from Torbenson Lancet 2003) Chronic infection Healthy carriage Recovery occult DNA Anti-HBe Anti-HBc Immune response.
Preparation of HBV DNA reference standards and the experience of HBV NAT in Taiwan Dr. Hwei-Fang Cheng Department of Health, Taiwan.
Maternofetal transmission of human parvovirus B19 genotype 3 in Ghana, West Africa D Candotti, K Danso, A Parsyan, A Dompreh, J- P Allain National Blood.
Serology - anti-HCV. anti-HIV, HBsAg NAT - HCV RNA - since 2000
An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.
Novel and Related Variant Parvoviruses in Human Plasma Jacqueline Fryer and Sally Baylis National Institute for Biological Standards and Control Eric Delwart.
Risk assessment: The Safety of Blood Products presented by Dr. Thomas R. Kreil Baxter BioScience on behalf of the PPTA Pathogen Safety Steering Committee.
A classic case of loosing options… Hans H Hirsch Transplantation & Clinical Virology Department Biomedicine (Haus Petersplatz) Division Infection Diagnostics.
E B—Anti-HBc Chart 1 10/2004 Anti-HBc Testing and Donor Reentry Results of a Pilot Study Susan L. Stramer, Ph.D. American Red Cross Blood Products.
February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.
Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.
A logcopies/ml b IU/ml HBV DNA levels ALT levels Figure S1.
A.Professor Gehan Lotfy abdel Hakeem Minia University Egypt
Hepatitis Tutoring By Alaina Darby.
In The Name of God.
Hepatitis B immune globulin
MICROBIOLOGY PRACTICAL
Ann Intern Med. 2017;167(1):1-7. doi: /M Figure Legend:
Human Parvovirus PARV4 in Blood and Plasma Products
Dr Iyat Abdul Sattar A study on the clinical & serolological markers of HBV among patients with chronic HBV infection in Babylon Dr Monem Makki Alshok.
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Organ Donor Infectious Disease Testing Education
Implementing NAT& Universal Parasitic Screening for Blood Donors
MICROBIOLOGY PRACTICAL
Benefits of apheresis collection
FACILITATOR VERSION Case Four: I just have antibodies to this
Lamivudine + INF - a At each visit: clinical examination, transaminase
دانشگاه علوم پزشکی بوشهر برنامه ملی مبارزه با بیماریهای واگیر
Update on WHO Projects.
Evaluation data on the new Roche cobas s 201 system with the cobas TaqScreen MPX test Lutz Pichl, Volkmar Schottstedt German Red Cross Blood Transfusion.
Viral Safety of Blood Products in Taiwan
Introduction The American Journal of Medicine
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Efficacy of Serologic Marker Screening in Identifying Hepatitis B Virus Infection in Organ, Tissue, and Cell Donors  Dominique Challine, Stéphane Chevaliez,
Figure 2 Distribution of markers of active HBV infection
SoGAT meeting XXI May (2009), Brussels, Belgium
Diagnostic value of quantitative PCR for adenovirus detection in stool samples as compared with antigen detection and cell culture in haematopoietic stem.
FACILITATOR VERSION Case Four: I just have antibodies to this
Role for HCV antigen detection: a new generation of assays
Volume 56, Issue 3, Pages (March 2012)
Presentation transcript:

HBV/G Infection of an Apheresis Donor 3 Platelet and 4 Plasma Pheresis Donations Positive in Indiv. Donation PCR 50 Apheresis Platelets Donations Follow-up 45 Plasma Pheresis x Follow-up samples 40 GPT (U/l) 35 Pool-PCR positive 30 Anti-HBs (IU/ml) GPT U/L 25 20 15 Anti-HBs (IU/ml) HBsAG 10 ID-PCR positive Anti-HBc 5 20 40 60 80 100 120 Days

HBV/G Infection of an Apheresis Donor 3 Platelet and 4 Plasma Pheresis Donations Positive in Indiv. Donation PCR x Apheresis Platelets Plasma Pheresis Follow-up samples Donations Follow-up 6,258 cp/ml Pool-PCR positive ID-PCR (Geq/ml) Look-Back 295 cp/ml 855 cp/ml Days

Pure HBV Genotyp G N D R3 R4 Marker Conj. control Amp. control Genotype A Genotype B Genotype C Genotype F Genotype G Genotype E Genotype D 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Genotype-specific Amplification of HBV/G

HBV/G: Viral Load and Prism s/co Recipient 4 Date NAT (copies/mL) Lab. X PEI Prism HBsAg S/Co 06/19 Not done 0.27 07/10 3,900 10,744 0.68 07/31 5,480 9,062 0.57 08/08 6,490 13,890 0.73 08/22 0.75